## Sridevi Rajeeve

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10122590/publications.pdf

Version: 2024-02-01

2258059 2053705 22 32 3 5 citations h-index g-index papers 22 22 22 28 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Advances, 2022, 6, 3433-3439.	5.2	5
2	Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2021, 62, 176-184.	1.3	7
3	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Advances, 2021, 5, 345-351.	5.2	7
4	Outcome of Superselective Bronchial Artery Embolization in Patients with Massive Hemoptysis. Indian Journal of Respiratory Care, 2021, 10, 107-111.	0.1	0
5	Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2021, 27, 205-212.	2.0	1
6	Factor XI Deficiency in Pregnant Women: A Case-Series from a New York City Hospital. Blood, 2020, 136, 16-16.	1.4	0
7	Impact of Additional Cytogenetic Abnormalities and Complex Karyotype on Event-Free Survival in Acute Promyelocytic Leukemia: Analysis from a Single Academic Center Plus the APML4 Study. Blood, 2020, 136, 34-35.	1.4	O
8	Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) at Admission Are Predictors for Worse Functional Outcome in Cerebral Venous Sinus Thrombosis. Blood, 2020, 136, 8-9.	1.4	0
9	NECROTIZING FASCIITIS TRIGGERED BY TRAUMA - BUT NOT TRAUMA. Chest, 2019, 156, A2023.	0.8	O
10	The Power of a Talisman. Journal of Graduate Medical Education, 2019, 11, 719-719.	1.3	0
11	Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT). Blood, 2019, 134, 2826-2826.	1.4	2
12	Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia. Blood, 2019, 134, 3816-3816.	1.4	3
13	Etiologies and Predictors of 30-Day Readmission in Patients Undergoing Induction Chemotherapy for Acute Myeloid Leukemia. Blood, 2019, 134, 4759-4759.	1.4	2
14	Myelodysplastic Syndromes: Trends in Mortality, Costs of Hospitalizations, Length of Stay and Rate of Complications. Blood, 2019, 134, 1725-1725.	1.4	0
15	Risk Factors and Trends for Incidence of Acute Coronary Syndrome after Hematopoietic Stem Cell Transplant - a 15-Year Experience with National Inpatient Sample. Blood, 2019, 134, 4564-4564.	1.4	O
16	Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality. Blood, 2019, 134, 3864-3864.	1.4	1
17	Survival for Relapsed/Refractory Hodgkin Lymphoma Patients with Recurrent or Persistent Disease Following Autologous Hematopoietic Stem Cell Transplantation Treated in the Modern Era. Blood, 2018, 132, 2148-2148.	1.4	1
18	Impact of clostridium difficile infection on mortality among gastrointestinal (GI) and lung cancers Journal of Clinical Oncology, 2018, 36, e18735-e18735.	1.6	0

#	Article	IF	CITATIONS
19	Impact of denosumab on skeletal-related events in solid tumors Journal of Clinical Oncology, 2018, 36, e18754-e18754.	1.6	0
20	Managing Inpatient Constipation: A Docusate Initiative. American Journal of Gastroenterology, 2018, 113, S639.	0.4	2
21	Opportunistic Infections, Is Non Hodgkin Lymphoma One of the Risk Factors for Mortality?. Blood, 2018, 132, 5818-5818.	1.4	1
22	Comparison of Rivaroxaban with Argatroban in Heparin Induced Thrombocytopenia Using Historical Controls: A Case-Control Study. Blood, 2018, 132, 4996-4996.	1.4	0